Pub Date : 2022-04-30DOI: 10.37285/ijpsn.2022.15.2.9
Biswajeet Acharya, P. K. Sahu, G. Pattnaik, A. Behera, Santosh Kumar Ranajit, Dinesh Kumar Sharma, A. Meher
Black fungus is the latest threat to the patients who just recovered from the covid-19. Black fungus is a type of mucormycosis infection, predominantly seen in patients with co-morbidities, mainly diabetes, cancer, immunocompromised infections, and organ transplant. Rising black fungus cases are not only a major aesthetic problem disrupting the medical and socioeconomic system, but it also senses another upcoming pandemic in India. Black fungus has a clinical appearance that is indistinguishable from other common illnesses at first, and it is invariably deadly unless diagnosed early or untreated vigorously. Rapid and precise diagnostic procedures, as well as the availability of less toxic, more effective antifungal drugs like posaconazole and isavuconazole, should be pursued as targets for improved black fungus care. The liposomal Amphotericin B had brought new rays of hope for treating black fungus by providing better efficacy amongst people. Since there is a dearth of literature regarding the management of black fungus patients, the article focused on the incidences, prevalence, diagnosis, and treatment protocol, to gain insight into the extent of this epidemic in India in 2021.
{"title":"Black Fungus: Pandemic Devastating India?","authors":"Biswajeet Acharya, P. K. Sahu, G. Pattnaik, A. Behera, Santosh Kumar Ranajit, Dinesh Kumar Sharma, A. Meher","doi":"10.37285/ijpsn.2022.15.2.9","DOIUrl":"https://doi.org/10.37285/ijpsn.2022.15.2.9","url":null,"abstract":"Black fungus is the latest threat to the patients who just recovered from the covid-19. Black fungus is a type of mucormycosis infection, predominantly seen in patients with co-morbidities, mainly diabetes, cancer, immunocompromised infections, and organ transplant. Rising black fungus cases are not only a major aesthetic problem disrupting the medical and socioeconomic system, but it also senses another upcoming pandemic in India. Black fungus has a clinical appearance that is indistinguishable from other common illnesses at first, and it is invariably deadly unless diagnosed early or untreated vigorously. Rapid and precise diagnostic procedures, as well as the availability of less toxic, more effective antifungal drugs like posaconazole and isavuconazole, should be pursued as targets for improved black fungus care. The liposomal Amphotericin B had brought new rays of hope for treating black fungus by providing better efficacy amongst people. Since there is a dearth of literature regarding the management of black fungus patients, the article focused on the incidences, prevalence, diagnosis, and treatment protocol, to gain insight into the extent of this epidemic in India in 2021.","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74563108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-28DOI: 10.37285/ijpsn.2022.15.1.8
Anjali Bedse, Ajinath Nikam, Aditi Kulkarni, V. Potnis, S. Dhamane
Dapsone is a Biopharmaceutical Classification System class II drug with anti inflammatory, immunosuppressive, antibacterial, and antibiotic properties and is used as an antileprotic. The purpose of the present study was to investigate the potential of a microemulsion formulation for topical delivery of dapsone to enhance permeation and to avoid systemic side effects. When administered orally, dapsone undergoes hepatic metabolism. Its hepatic metabolite, dapsone hydroxylamine, shows systemic side effects such as hemolytic anaemia peripheral neuropathy, nausea, and headache. A novel drug delivery system in the form of a microemulsion was developed for dapsone. This is the first attempt that dapsone has been combined with chaulmoogra oil in a topical microemulsion. The primary drugs used for the treatment of leprosy are found in chaulmoogra seeds. Considering its good solubilizing capacity and its use in the treatment of leprosy, chaulmoogra oil was chosen as the oil phase. Based on emulsification ability, Cremophor RH40 and PEG 400 were selected as surfactant and co-surfactant, respectively. A pseudo-ternary phase diagram was constructed to identify the microemulsion region. Smix (Cremophor RH40: PEG-400 in the ratio of 1:2) was most effective in imparting stability to the formulation. The selected formulation exhibited appropriate diffusion behavior (in vitro). The developed dapsone containing microemulsion formulation exhibited the optimal homogeneity, clarity, pH, type of microemulsion, viscosity, percent drug content, and percent transmittance to qualify as a topical drug delivery system for local treatment of leprosy.
{"title":"Development and Characterization of topical microemulsion as novel drug delivery system for Dapsone","authors":"Anjali Bedse, Ajinath Nikam, Aditi Kulkarni, V. Potnis, S. Dhamane","doi":"10.37285/ijpsn.2022.15.1.8","DOIUrl":"https://doi.org/10.37285/ijpsn.2022.15.1.8","url":null,"abstract":"Dapsone is a Biopharmaceutical Classification System class II drug with anti inflammatory, immunosuppressive, antibacterial, and antibiotic properties and is used as an antileprotic. The purpose of the present study was to investigate the potential of a microemulsion formulation for topical delivery of dapsone to enhance permeation and to avoid systemic side effects. When administered orally, dapsone undergoes hepatic metabolism. Its hepatic metabolite, dapsone hydroxylamine, shows systemic side effects such as hemolytic anaemia peripheral neuropathy, nausea, and headache. A novel drug delivery system in the form of a microemulsion was developed for dapsone. This is the first attempt that dapsone has been combined with chaulmoogra oil in a topical microemulsion. The primary drugs used for the treatment of leprosy are found in chaulmoogra seeds. Considering its good solubilizing capacity and its use in the treatment of leprosy, chaulmoogra oil was chosen as the oil phase. Based on emulsification ability, Cremophor RH40 and PEG 400 were selected as surfactant and co-surfactant, respectively. A pseudo-ternary phase diagram was constructed to identify the microemulsion region. Smix (Cremophor RH40: PEG-400 in the ratio of 1:2) was most effective in imparting stability to the formulation. The selected formulation exhibited appropriate diffusion behavior (in vitro). The developed dapsone containing microemulsion formulation exhibited the optimal homogeneity, clarity, pH, type of microemulsion, viscosity, percent drug content, and percent transmittance to qualify as a topical drug delivery system for local treatment of leprosy. ","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86052819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-28DOI: 10.37285/ijpsn.2022.15.1.1
Bikash Medhi Bikash Medhi
Introduction The word 'nano' refers to a Greek prefix that means 'dwarf' or very little,' and represents a thousand millionth of a meter (10-9) in length. Nanoscience and nanotechnology are the study and application of nanoscale range materials. Initially, the term Nanotechnology was used by N. Taniguchi in 1974 at an international conference on industrial production in Tokyo to characterize the super-thin processing of materials with nanometre accuracy and the fabrication of nano-sized systems (Bayda S. et al., 2020). The usage of nanomaterials has enhanced the application of nanomedicine in various therapeutics area with challenges and limitations over the last ten years. Alteration of the physiochemical, biological, mechanical & other properties of the materials made the nanomaterials and it can be utilized in different useful activities such as drug development, drug target. Nanotechnology utilized novel nanomaterials to make useful products. This technology has been used to overcome the limitations & challenges in different drug therapies. (Harea JI et al., 2017). The combination of nanotechnology with pharmaceuticals and biomedicals is termed nano pharmaceutical. Nanopharmaceuticals is a new technology in current practice. As a result, there are no widely agreed nanopharmaceuticals guidelines. The general idea of regulatory requirements for Active Pharmaceutical Ingredients (API), as stated in the CDSCO's New Drugs and Clinical Trial Rules 2019, was mandatory in drug development pathways. These criteria are also in line with the International Council for Harmonization (ICH) recommendations and international standards that other countries using such items follow. New Drugs and Clinical Trials Rules, 2019 should be followed in different drug development. (Harea JI et al., 2017). Globally, there are important guidelines developed by the United States Food & Drugs Administration (USFDA), International Council for Harmonization (ICH), or Organization for Economic Co-operation and Development (OECD). (Harea JI et al., 2017). Current regulatory approaches by US Food & Drug Administration (FDA), established the nanotechnology task force in August 2006. This regulatory approach encourages the development of nanoproducts. FDA has issued the guidelines in 2007 to the industry to address the benefits & risks of Drugs, medical devices, and other nanoproducts. FDA is also working with other U.S. government agencies to focus on the safety & efficacy of nanoproducts and U.S. initiates the National Nanotechnology Initiative (NNI) which is a federal research & development program to coordinate the effort of all government agencies involved in nanotechnology. The main goal of the NNI is to maintain the class of research & development program, encourage inducing the new technologies in the product, developing the supporting infrastructure & tools needed for nanotechnology (Ventola et al., 2012).
“纳米”一词来源于希腊语的前缀，意思是“矮小”或“非常小”，它代表了一米的十亿分之一(10-9)的长度。纳米科学和纳米技术是纳米尺度材料的研究和应用。最初，纳米技术一词是由N. Taniguchi于1974年在东京举行的工业生产国际会议上使用的，用于表征具有纳米精度的材料超薄加工和纳米级系统的制造(Bayda S. et al.， 2020)。近十年来，纳米材料的使用促进了纳米医学在各个治疗领域的应用，但也面临着挑战和局限。纳米材料是通过改变材料的理化、生物、力学等特性而制成的，可用于药物开发、药物靶标等不同的有用活动。纳米技术利用新颖的纳米材料制造有用的产品。该技术已被用于克服各种药物治疗的局限性和挑战。(Harea JI et al.， 2017)。纳米技术与药物和生物医学的结合被称为纳米制药。纳米药物是当前实践中的一项新技术。因此，目前还没有得到广泛认可的纳米药物指南。CDSCO《2019年新药和临床试验规则》中规定的活性药物成分(API)监管要求的总体思路在药物开发途径中是强制性的。这些标准也符合国际协调理事会(ICH)的建议以及其他使用此类物品的国家遵循的国际标准。《新药和临床试验规则》，2019年应遵循不同药物的开发。(Harea JI et al.， 2017)。在全球范围内，美国食品和药物管理局(USFDA)、国际协调理事会(ICH)或经济合作与发展组织(OECD)制定了重要的指导方针。(Harea JI et al.， 2017)。美国食品和药物管理局(FDA)在2006年8月建立了纳米技术工作组。这种监管方法鼓励了纳米产品的开发。FDA在2007年向业界发布了指导方针，以解决药物、医疗器械和其他纳米产品的利益和风险。FDA还与其他美国政府机构合作，重点关注纳米产品的安全性和有效性，美国发起了国家纳米技术倡议(NNI)，这是一项联邦研究与开发计划，旨在协调所有涉及纳米技术的政府机构的努力。NNI的主要目标是维持研究和开发项目的等级，鼓励在产品中引入新技术，开发纳米技术所需的支持基础设施和工具(Ventola等人，2012)。
{"title":"Guidelines for Nano pharmaceutical products for regulatory approval","authors":"Bikash Medhi Bikash Medhi","doi":"10.37285/ijpsn.2022.15.1.1","DOIUrl":"https://doi.org/10.37285/ijpsn.2022.15.1.1","url":null,"abstract":"Introduction \u0000The word 'nano' refers to a Greek prefix that means 'dwarf' or very little,' and represents a thousand millionth of a meter (10-9) in length. Nanoscience and nanotechnology are the study and application of nanoscale range materials. Initially, the term Nanotechnology was used by N. Taniguchi in 1974 at an international conference on industrial production in Tokyo to characterize the super-thin processing of materials with nanometre accuracy and the fabrication of nano-sized systems (Bayda S. et al., 2020). The usage of nanomaterials has enhanced the application of nanomedicine in various therapeutics area with challenges and limitations over the last ten years. Alteration of the physiochemical, biological, mechanical & other properties of the materials made the nanomaterials and it can be utilized in different useful activities such as drug development, drug target. Nanotechnology utilized novel nanomaterials to make useful products. This technology has been used to overcome the limitations & challenges in different drug therapies. (Harea JI et al., 2017). \u0000The combination of nanotechnology with pharmaceuticals and biomedicals is termed nano pharmaceutical. Nanopharmaceuticals is a new technology in current practice. As a result, there are no widely agreed nanopharmaceuticals guidelines. The general idea of regulatory requirements for Active Pharmaceutical Ingredients (API), as stated in the CDSCO's New Drugs and Clinical Trial Rules 2019, was mandatory in drug development pathways. These criteria are also in line with the International Council for Harmonization (ICH) recommendations and international standards that other countries using such items follow. New Drugs and Clinical Trials Rules, 2019 should be followed in different drug development. (Harea JI et al., 2017). \u0000 Globally, there are important guidelines developed by the United States Food & Drugs Administration (USFDA), International Council for Harmonization (ICH), or Organization for Economic Co-operation and Development (OECD). (Harea JI et al., 2017). \u0000 Current regulatory approaches by US Food & Drug Administration (FDA), established the nanotechnology task force in August 2006. This regulatory approach encourages the development of nanoproducts. FDA has issued the guidelines in 2007 to the industry to address the benefits & risks of Drugs, medical devices, and other nanoproducts. FDA is also working with other U.S. government agencies to focus on the safety & efficacy of nanoproducts and U.S. initiates the National Nanotechnology Initiative (NNI) which is a federal research & development program to coordinate the effort of all government agencies involved in nanotechnology. The main goal of the NNI is to maintain the class of research & development program, encourage inducing the new technologies in the product, developing the supporting infrastructure & tools needed for nanotechnology (Ventola et al., 2012). ","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87756474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-28DOI: 10.37285/ijpsn.2022.15.1.3
Prashant Gupta, D. Patel
Dermatological products are being used for treating skin infections and pain /inflammation related disease from ancient times. The topical drug delivery provides many advantages over the other routes of drug administration. Apart from conventional dosage forms like creams, powders, lotions, gels, ointments, researchers are exploring new modifications in the dosage form for improved drug penetrations and enhanced pharmacodynamic activity of poorly absorbed drugs from the skin. Existing topical formulations are associated with the problems like stability, stickiness, irritation, lower spreadability, limited drug permeability and absorption. Formulation of Nano-emulsion based gels (Emulgel) is proved to be prominent approach for overcoming the barriers associated with the conventional dosage forms. Emulgels are prepared by screening oils, surfactant and co-surfactant on the basis of drug solubility. Nano-Emulsion is prepared using suitable techniques and then embedded into the gel matrix for skin application. Drug present in the oil portion in the micelles form (less than 500nm globule size) provides more area for absorption thereby more penetration and therapeutic activity. Emulgel processes desirable properties like greaseless, spreadability, emollient, non-staining, good consistency and improved organoleptic characteristics. Permeations enhancers are also explored for enhancing the penetration of drug incorporated in the Emulgel.
{"title":"A Review on nano-emulsion based gel formulations: emulgel, technology and recent advances","authors":"Prashant Gupta, D. Patel","doi":"10.37285/ijpsn.2022.15.1.3","DOIUrl":"https://doi.org/10.37285/ijpsn.2022.15.1.3","url":null,"abstract":"Dermatological products are being used for treating skin infections and pain /inflammation related disease from ancient times. The topical drug delivery provides many advantages over the other routes of drug administration. Apart from conventional dosage forms like creams, powders, lotions, gels, ointments, researchers are exploring new modifications in the dosage form for improved drug penetrations and enhanced pharmacodynamic activity of poorly absorbed drugs from the skin. Existing topical formulations are associated with the problems like stability, stickiness, irritation, lower spreadability, limited drug permeability and absorption. Formulation of Nano-emulsion based gels (Emulgel) is proved to be prominent approach for overcoming the barriers associated with the conventional dosage forms. Emulgels are prepared by screening oils, surfactant and co-surfactant on the basis of drug solubility. Nano-Emulsion is prepared using suitable techniques and then embedded into the gel matrix for skin application. Drug present in the oil portion in the micelles form (less than 500nm globule size) provides more area for absorption thereby more penetration and therapeutic activity. Emulgel processes desirable properties like greaseless, spreadability, emollient, non-staining, good consistency and improved organoleptic characteristics. Permeations enhancers are also explored for enhancing the penetration of drug incorporated in the Emulgel. ","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76034421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-28DOI: 10.37285/ijpsn.2022.15.1.5
D. Devendra, Dr.Akash Singh Panwar Akash, Dr.Megha Verma, Pradeepgolani, Sanjay A Nagdev
The pharmaceutical and healthcare industries have benefited greatly from artificial intelligence in recent years. A wide range of pharmaceutical fields, such as this novel approach, showed potential in drug discovery, continuous manufacturing (CM), dosage form design, and quality control. This article focuses on the use of artificial intelligence in the pharmaceutical sector. Before all else, the film sheds light on how AI will be implemented into health care, as well as its potential benefits. To conclude, there are several hurdles to overcome in the project implementation. At present, it's no secret that artificial intelligence (AI) and genetic algorithms (ANNs) are becoming increasingly popular in the pharmaceutical industry. In the pharmaceutical industry, artificial intelligence (AI) has shown promise, and it can be used in combination with robotics. Physical robots could revolutionize the healthcare industry. To keep their minds sharp and alert, it's used as a social interaction guide with elderly patients. In the pharmaceutical industry, artificial intelligence (AI) will help reduce costs and time.
{"title":"Impact of artificial intelligence in the pharmaceutical industry on working culture: Review","authors":"D. Devendra, Dr.Akash Singh Panwar Akash, Dr.Megha Verma, Pradeepgolani, Sanjay A Nagdev","doi":"10.37285/ijpsn.2022.15.1.5","DOIUrl":"https://doi.org/10.37285/ijpsn.2022.15.1.5","url":null,"abstract":"The pharmaceutical and healthcare industries have benefited greatly from artificial intelligence in recent years. A wide range of pharmaceutical fields, such as this novel approach, showed potential in drug discovery, continuous manufacturing (CM), dosage form design, and quality control. This article focuses on the use of artificial intelligence in the pharmaceutical sector. Before all else, the film sheds light on how AI will be implemented into health care, as well as its potential benefits. To conclude, there are several hurdles to overcome in the project implementation. At present, it's no secret that artificial intelligence (AI) and genetic algorithms (ANNs) are becoming increasingly popular in the pharmaceutical industry. In the pharmaceutical industry, artificial intelligence (AI) has shown promise, and it can be used in combination with robotics. Physical robots could revolutionize the healthcare industry. To keep their minds sharp and alert, it's used as a social interaction guide with elderly patients. In the pharmaceutical industry, artificial intelligence (AI) will help reduce costs and time. ","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87988353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.37285/ijpsn.2021.14.6.1
K. V. Madhav, Aksa Maheen, Kiranmai Mandhava
In customary medication, the greater part of infections has been treated by reveling of plant or plant items. As indicated by the Ayurveda individual herbs are deficient to accomplish an ideal restorative impact. To conquer this issue numerous spice structure in certain proportion is utilized that will give a superior restorative impact in better manner with decreased harmfulness. To grow such mediation, current examination will address about polyherbal formulation uses and its outline in treatment of different diseases and ailments. Home grown medications have existed worldwide since long time ago, therefore they bear history, and they were utilized in Chinese, Egyptian and Indian medications for different treatment. This review primarily centers around significance of polyherbal and its clinical importance.
{"title":"Poly-Herbal Formulations: Current Status and Future Perspectives for Treatment of Various Complications","authors":"K. V. Madhav, Aksa Maheen, Kiranmai Mandhava","doi":"10.37285/ijpsn.2021.14.6.1","DOIUrl":"https://doi.org/10.37285/ijpsn.2021.14.6.1","url":null,"abstract":"In customary medication, the greater part of infections has been treated by reveling of plant or plant items. As indicated by the Ayurveda individual herbs are deficient to accomplish an ideal restorative impact. To conquer this issue numerous spice structure in certain proportion is utilized that will give a superior restorative impact in better manner with decreased harmfulness. To grow such mediation, current examination will address about polyherbal formulation uses and its outline in treatment of different diseases and ailments. Home grown medications have existed worldwide since long time ago, therefore they bear history, and they were utilized in Chinese, Egyptian and Indian medications for different treatment. This review primarily centers around significance of polyherbal and its clinical importance. ","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"84 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75908593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.37285/ijpsn.2021.14.6.5
V. Manam, S. Murugesan
The biosynthesized silver nanoparticles from marine red seaweed Halymenia porphyroides against Dalton’s lymphoma ascites (DLA)-induced tumor inoculation was studied for antitumor activity. The biosynthesized silver nanoparticles from marine red seaweed Halymenia porphyroides were given orally to Swiss albino mice (50 mg/kg/day) for 14 days showed a significant reduction in body weight, packed cell volume, andviable tumor cell count when compared to the mice of the DLA control group.The haematological parameters of the treatment group with biosynthesized silver nanoparticles also exhibited increased haemoglobin, RBCs, Platelets, and decreased WBCs compared to the DLA control group of mice. Similarly, the biochemical parameters like total cholesterol, aspartate amino-transferase (AST), alanine aminotransferase (ALT), triglycerides (TL), and alkaline phosphatase (ALP) of the treatment control group with biosynthesized silver nanoparticles reversed the parameters to normal levels compared to the DLA control group of mice. The antitumor efficacy of the biosynthesized silver nanoparticles from Halymenia porphyroides was confirmed based on the haematological, biochemical, life span, packed cell volume, cell count, and histopathological analysis.
{"title":"Antitumor Efficacy of Silver Nanoparticles Biosynthe-sized from Marine Red Seaweed Halymenia porphyroides Boergesen on Dalton’s Lymphoma Ascites in Mice","authors":"V. Manam, S. Murugesan","doi":"10.37285/ijpsn.2021.14.6.5","DOIUrl":"https://doi.org/10.37285/ijpsn.2021.14.6.5","url":null,"abstract":"The biosynthesized silver nanoparticles from marine red seaweed Halymenia porphyroides against Dalton’s lymphoma ascites (DLA)-induced tumor inoculation was studied for antitumor activity. The biosynthesized silver nanoparticles from marine red seaweed Halymenia porphyroides were given orally to Swiss albino mice (50 mg/kg/day) for 14 days showed a significant reduction in body weight, packed cell volume, andviable tumor cell count when compared to the mice of the DLA control group.The haematological parameters of the treatment group with biosynthesized silver nanoparticles also exhibited increased haemoglobin, RBCs, Platelets, and decreased WBCs compared to the DLA control group of mice. Similarly, the biochemical parameters like total cholesterol, aspartate amino-transferase (AST), alanine aminotransferase (ALT), triglycerides (TL), and alkaline phosphatase (ALP) of the treatment control group with biosynthesized silver nanoparticles reversed the parameters to normal levels compared to the DLA control group of mice. The antitumor efficacy of the biosynthesized silver nanoparticles from Halymenia porphyroides was confirmed based on the haematological, biochemical, life span, packed cell volume, cell count, and histopathological analysis. ","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73565179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.37285/ijpsn.2021.14.6.7
Deep Patel, Deepa H. Patel, D. Talele
Nanoliposomes were prepared using solvent injection method and topical spray using simple dispersion method. The particle size and % Entrapment Efficiency were found 18.01 ± 0.21 nm and 87.71 ± 0.12% respectively. TEM studies showed that the particles were in spherical shape. Drying time, volume per spray, area of film and dose uniformity were found to be 280 ± 0.002 sec, 0.16± 0.021 ml, 155.57 ± 0.012 cm2 and 0.15± 0.0012 ml respectively which showed good spraying conditions on the affected area. Stability study shows that dapsone and chaulmoogra oil loaded nanoliposomal topical spray was stable at accelerated condition up to 1 month. The present investigation provides a safe approach by improving the outer membrane permeability to combat microbial drug resistance and increasing safety in leprosy treatment.
{"title":"Nanoliposomal Topical Formulation for Increasing Safety and Combating Microbial Drug Resistance in Leprosy","authors":"Deep Patel, Deepa H. Patel, D. Talele","doi":"10.37285/ijpsn.2021.14.6.7","DOIUrl":"https://doi.org/10.37285/ijpsn.2021.14.6.7","url":null,"abstract":"Nanoliposomes were prepared using solvent injection method and topical spray using simple dispersion method. The particle size and % Entrapment Efficiency were found 18.01 ± 0.21 nm and 87.71 ± 0.12% respectively. TEM studies showed that the particles were in spherical shape. Drying time, volume per spray, area of film and dose uniformity were found to be 280 ± 0.002 sec, 0.16± 0.021 ml, 155.57 ± 0.012 cm2 and 0.15± 0.0012 ml respectively which showed good spraying conditions on the affected area. Stability study shows that dapsone and chaulmoogra oil loaded nanoliposomal topical spray was stable at accelerated condition up to 1 month. The present investigation provides a safe approach by improving the outer membrane permeability to combat microbial drug resistance and increasing safety in leprosy treatment. ","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81434534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.37285/ijpsn.2021.14.6.8
Harshita Gupta, Ashish K. Srivastava
Present work illustrates that efavirenz-loaded solid lipid nanoparticles were prepared with the objective of increasing bioavailability and protection of drugs due to biocompatible lipidic content. Efavirenz is generally used for the treatment of HIV. Selection of the suitable lipid phase, surfactant, and cosurfactant was done by individual screening method with the construction of pseudo-ternary phase study. The formulations were prepared by the microemulsion method followed by the lyophilization technique. EFV-SLN has shown a mean particle size of 55.73 ± 3.9 nm having a PDI of 0.153 ± 0.451. Zeta potential was found to be -9.98mV and the formulation was found stable. In vivo pharmaco-kinetic studies exhibited 5.41-fold enhancement in peak plasma concentration (
{"title":"Design and Evaluation of Efavirenz Loaded Solid Lipid Nanoparticle for Boosting Oral Bioavailability","authors":"Harshita Gupta, Ashish K. Srivastava","doi":"10.37285/ijpsn.2021.14.6.8","DOIUrl":"https://doi.org/10.37285/ijpsn.2021.14.6.8","url":null,"abstract":"Present work illustrates that efavirenz-loaded solid lipid nanoparticles were prepared with the objective of increasing bioavailability and protection of drugs due to biocompatible lipidic content. Efavirenz is generally used for the treatment of HIV. Selection of the suitable lipid phase, surfactant, and cosurfactant was done by individual screening method with the construction of pseudo-ternary phase study. The formulations were prepared by the microemulsion method followed by the lyophilization technique. EFV-SLN has shown a mean particle size of 55.73 ± 3.9 nm having a PDI of 0.153 ± 0.451. Zeta potential was found to be -9.98mV and the formulation was found stable. In vivo pharmaco-kinetic studies exhibited 5.41-fold enhancement in peak plasma concentration (","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83191763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01DOI: 10.37285/ijpsn.2021.14.6.3
K. Agrawal, Y. Murti, Jyoti, N. Agrawal, Tripanshu Gupta
The most common type of cancer and the second biggest cause of death is breast cancer. The disease is the leading cause of death in women aged 45 to 55. It's a multi-stage disease in which viruses have a role in one stage. Breast cancer is an illness that affects the sufferer, their family, and the entire community all over the world. Breast cancer has no established cause, however specific risk factors have been found. Age, race, gender, and family history are all fixed and immutable characteristics. Other elements, such as social and familial support, can help to mitigate the harmful effects.The aim of the present study was to investigate the bioactive ligand for the breast cancer treatment against the HER2 and ESR1 proteins by molecular docking studies. HER2 is an oncogene and membrane tyrosine kinase that is overexpressed and gene amplified in about 20% of breast tumours. When active, it sends proliferative and anti-apoptotic signals to the cell. It is the most important factor in the genesis and progression of breast cancer tumours. To carry out this work protein structures were download from the PDB database and ligands three dimensional structures were downloaded from the PubChem database. The docking was performed by using the iGEMDOCK software suit. The binding energies of bioactive molecules from Hibiscus rosa-sinensis were found to be Rutin (-139.779, -102.743), Quercetin (-106.5, -99.7807), Kaempferol (-105.824, -92.5271), Myricetin (-111.913, -99.603) and Methotrexate (-140.69, -130.165) against HER2 and ESR1 proteins respectively. Lowest energy of Rutin compared to Methotrexate showed highest binding among the other bioactive molecules.The binding energies of the molecules are the sum of hydrogen bond, vanderwaal’s and electrostatic energies that inversely linked to protein-ligand interaction. From the result of the current study we can conclude that among the four bioactive molecule rutin has lowest binding energy so it could be used as an inhibitor of HER2 and ESR1 protein for the treatment of breast carcinoma in future.
{"title":"In Silico Studies of Bioactive Compounds from Hibiscus rosa-sinensis Against HER2 and ESR1 for Breast Cancer Treatment","authors":"K. Agrawal, Y. Murti, Jyoti, N. Agrawal, Tripanshu Gupta","doi":"10.37285/ijpsn.2021.14.6.3","DOIUrl":"https://doi.org/10.37285/ijpsn.2021.14.6.3","url":null,"abstract":"The most common type of cancer and the second biggest cause of death is breast cancer. The disease is the leading cause of death in women aged 45 to 55. It's a multi-stage disease in which viruses have a role in one stage. Breast cancer is an illness that affects the sufferer, their family, and the entire community all over the world. Breast cancer has no established cause, however specific risk factors have been found. Age, race, gender, and family history are all fixed and immutable characteristics. Other elements, such as social and familial support, can help to mitigate the harmful effects.The aim of the present study was to investigate the bioactive ligand for the breast cancer treatment against the HER2 and ESR1 proteins by molecular docking studies. HER2 is an oncogene and membrane tyrosine kinase that is overexpressed and gene amplified in about 20% of breast tumours. When active, it sends proliferative and anti-apoptotic signals to the cell. It is the most important factor in the genesis and progression of breast cancer tumours. To carry out this work protein structures were download from the PDB database and ligands three dimensional structures were downloaded from the PubChem database. The docking was performed by using the iGEMDOCK software suit. The binding energies of bioactive molecules from Hibiscus rosa-sinensis were found to be Rutin (-139.779, -102.743), Quercetin (-106.5, -99.7807), Kaempferol (-105.824, -92.5271), Myricetin (-111.913, -99.603) and Methotrexate (-140.69, -130.165) against HER2 and ESR1 proteins respectively. Lowest energy of Rutin compared to Methotrexate showed highest binding among the other bioactive molecules.The binding energies of the molecules are the sum of hydrogen bond, vanderwaal’s and electrostatic energies that inversely linked to protein-ligand interaction. From the result of the current study we can conclude that among the four bioactive molecule rutin has lowest binding energy so it could be used as an inhibitor of HER2 and ESR1 protein for the treatment of breast carcinoma in future. ","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78068550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：